EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSMMMG00000018086
Gene Symbol: NR3C1
3 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSMMMG00000002054
Gene Symbol: NR3C2
3 Cross references
212 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSMMMG00000013415
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSMMMG00000012823
Gene Symbol: OPRD1
3 Cross references
252 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSMMMG00000000792
Gene Symbol: OPRK1
3 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSMMMG00000003833
Gene Symbol: OPRM1
3 Cross references
214 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSMMMG00000000168
Gene Symbol: OPRL1
1 Cross references
199 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSMMMG00000008417
Gene Symbol: OXTR
3 Cross references
262 Possible Orthologues:

Pancreatic Alpha-Amylase-Like

Ensembl ID : ENSMMMG00000008564
Gene Symbol: LOC107156534
2 Cross references
213 Possible Orthologues:

Pancreatic Triacylglycerol Lipase

Ensembl ID : ENSMMMG00000018656
Gene Symbol: LOC107152947
2 Cross references
279 Possible Orthologues:

Pancreatic Triacylglycerol Lipase-Like

Ensembl ID : ENSMMMG00000018544
Gene Symbol: LOC107152946
2 Cross references
291 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSMMMG00000006794
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).